Achieve Life Sciences, Inc.

NASDAQ:ACHV

Biotechnology

Healthcare
$6.78 -7.00%

-$0.38 today

Market cap
$697.68M
Beta
2.26
P/E (TTM)
-5.1
EPS (TTM)
-$0.97
52W Low $2.00High $6.16

Volume 1.09M

Average 1.44M

ACHV Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Achieve Life Sciences, Inc.NASDAQ: ACHV

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $3.29M fell 53.6% year over year, behind the -29.2% change in trailing-twelve-month research & development. Sequentially, it fell 15.0% from the prior quarter. Over 3 fiscal years it compounded at -8.6% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -53.6% toward the trailing-twelve-month pace of -29.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.29M-15.0% QoQ
Last fiscal yearDec 2025
$22.96M+0.6% YoY
LTMMar 2026
$19.19M-29.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-53.6%——
1 year+0.6%——
3-year CAGR-8.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
22.96M USD
Year-over-year change
+0.6%
4-year CAGR
-1.1%

Research & Development vs competitors

How ACHV compares with its peers on the latest reported figures

No competitor Research & Development figures are available to compare.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue000229K228K
Gross Profit000(229K)(228K)
Gross Margin—————
Research & Development23.97M30.08M15.81M22.82M22.96M
Selling, General & Admin9.13M10.72M11.44M16.25M31.87M
Operating Expenses33.09M40.8M27.25M38.84M54.65M
Depreciation & Amortization250K236K228K229K228K
EBITDA(32.9M)(40.33M)(26.73M)(37.42M)(53.6M)
EBITDA Margin—————
Operating Income(33.09M)(40.8M)(27.25M)(39.07M)(54.88M)
Operating Margin—————
Interest Income17K199K825K2.36M1.5M
Interest Expense01.79M2.85M2.18M819K
Other Income / Expenses(58K)(1.55M)(2.57M)(758K)232K
Income Before Tax(33.15M)(42.35M)(29.82M)(39.83M)(54.65M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(33.15M)(42.35M)(29.82M)(39.83M)(54.65M)
Net Margin—————
EPS (Basic)(4.05)(3.95)(1.50)(1.24)(1.25)
EPS (Diluted)(4.05)(3.95)(1.50)(1.24)(1.25)
Weighted Avg Shares8.12M10.59M19.83M32.07M43.59M
Weighted Avg Shares (Diluted)8.12M10.59M19.83M32.07M43.59M

Achieve Life Sciences, Inc.

NASDAQ:ACHV

Intrinsic Alpha fair value

Locked

Current Price

$6.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.